 2020 Q3 Earnings Summary

Chemed Corporation reported its Q3 2020 earnings, with VITAS Healthcare Corporation subsidiary and Roto-Rooter showing operational improvement from Q2 2020. VITAS' admissions increased by 4.7% in Q3 2020, with a decline in average daily census of 2/10ths of 1%. Roto-Rooter's commercial demand declined by 11.6% in Q3 2020 when compared to the prior year quarter, but residential demand set all-time records with a 22.8% increase in July 2020. Chemed is forecasted to achieve full year 2020 revenue growth of 12.5% to 13%, with Roto-Rooter achieving full year 2020 revenue growth of 12.5%. Chemed's full year 2020 adjusted earnings per diluted share, excluding non-cash expense for stock options, tax benefits for stock options, costs related to litigation and other discrete items, is estimated to be in the range of $18 to $18.15.